ASPI founders have researched this prescription medicine for years. It has finally made it to an AS Clinical Trial.

A phase 3 trial for men with lower risk prostate cancer is open for enrollment. The ProVent trial will assess the efficacy of immunotherapy (sipuleucel-T, brand name PROVENGE ® ) in reducing disease progression in men with lower risk prostate cancer on Active Surveillance (AS).

Sipuleucel-T uses a patient’s own cells to stimulate the body’s immune system to target and attack the prostate cancer cells. The life-saving effects of immunotherapy treatment with sipuleucel-T have been proven in some men with advanced prostate cancer (also referred to as metastatic castrate-resistant prostate cancer or mCRPC), and research suggests that this cutting-edge therapy may also benefit men with lower risk prostate cancer who are on AS.

Nearly 175,000 men are diagnosed with prostate cancer every year. Of these, about 30 to 40% will opt for AS, which has grown in popularity as a treatment option for men with lower risk prostate cancer and includes regular prostate-specific antigen (PSA) testing and tumor biopsies (every 1-2 years) to ensure the cancer is not growing or spreading. Choosing AS may allow some men to delay – or even avoid – surgery and radiation, which often result in life-altering side effects.

The investigational ProVent trial will evaluate the effectiveness of sipuleucel-Tin reducing disease progression in men with lower risk prostate cancer who are candidates for AS and looking for a proactive alternative to surgery or radiation. The multi-center ProVent trial is being conducted at approximately 50 sites in the U.S. ProVent will enroll 450 men age 18 or older diagnosed with lower risk prostate cancer within 12 months of enrollment. Study participants will be randomized 2:1. This means that for every 2 participants that receive sipuleucel-T, 1 will receive the standard treatment protocol for AS.

ProVentStudy.com or call (800) 772-3125. When prompted, enter study code number: 170101 (do not hit the #, hash or number key).